ClinicalTrials.gov
public full text
Public Domain
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
This phase I study has been designed to establish the safety, tolerability and maximum tolerated dose (MTD) of four separate regimens for patients with metastatic breast cancer: dose- escalating BKM120 when combined with capecitabine (Arm A), with capecitabine and trastuzumab (Arm C), or with capecitabine and lapatinib (Arm D) and dose- escalating BEZ235 when combined with capecitabine (Arm B).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC#1093495
- Gemcitabine + Carboplatin in Breast Cancer#909131
- Capecitabine in ER+/HER2-negative Breast Cancer#1114541
- Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations#806928
- A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors#1102496
Record · ID 1032029
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive